SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

14 Nov 2022 Evaluate
The September 2022 quarter revenue stood at Rs. 3886.47 millions, up 6.60% as compared to Rs. 3645.69 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2022 is Rs. -224.68 millions as compared to Net Profit of Rs. 18.62 millions of corresponding quarter ended September 2021The company reported a degrowth in operating Profit to 33.10 millions from 325.55 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 3886.47 3645.69 6.60 7916.70 7490.22 5.69 16682.56 15428.96 8.12
Other Income 107.10 50.97 110.12 110.74 102.43 8.11 112.93 27.22 314.88
PBIDT 33.10 325.55 -89.83 455.19 733.42 -37.94 1701.31 1129.49 50.63
Interest 209.88 180.09 16.54 423.54 437.54 -3.20 788.10 1120.32 -29.65
PBDT -176.78 145.46 -221.53 31.65 295.88 -89.30 913.21 -243.98 -474.30
Depreciation 147.91 141.54 4.50 294.86 284.32 3.71 569.68 602.53 -5.45
PBT -324.69 3.92 -8382.91 -263.21 11.56 -2376.90 343.53 -846.51 -140.58
TAX -100.01 -14.70 580.34 -77.89 -27.75 180.68 90.34 -115.04 -178.53
Deferred Tax -100.01 -14.70 580.34 -77.89 -27.75 180.68 90.34 -200.90 -144.97
PAT -224.68 18.62 -1306.66 -185.32 39.31 -571.43 253.19 -731.47 -134.61
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 0.74 7.75 -90.46 5.75 9.79 -41.28 8.84 6.41 37.98

Nectar Lifesciences Share Price

12.66 0.25 (2.01%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×